Association of FGF-23 with silent lupus nephritis

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08889
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54020:Connective tissue disease and allergy-related
• Research Institution: Keio University
• Principal Investigator: Hanaoka Hironari 慶應義塾大学, 医学部(信濃町), 講師 (90453547)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 全身性エリテマトーデス

Outline of Final Research Achievements

Objective of this study was to evaluate the association of FGF-23 with renal outcome in systemic lupus erythematosus (SLE). We included 109 patients with SLE and divided into 2 groups according to the presence of proteinuria or active sediment. Clinical features, urine biomarkers (b2 microgloburin, a1 microgloburin, NAG, NGAL, amd L-FABP), FGF-23 and cumulative renal deterioration rate were compared. We found 60 patients with and 49 patients without proteinuria or active sediment and there was no significant difference between the 2 groups in the cumulative renal deterioration rate (p=0.32). Regarding with clinical features, patients with proteinurina or active sediment had higher disease activity (systemic lupus erythemaosus activity index) than those without (p=0.02). We could not find any difference in urine biomaker or serum FGF-23 between the 2 groups. Patients may progress renal dysfunction regardless peroteinuria or active sediment and FGF-23 may contribute to the status.

Free Research Field

リウマチ膠原病学

Academic Significance and Societal Importance of the Research Achievements

検尿異常の乏しいSLE患者の長期腎予後に関する報告は少なく、関係する因子についても希少である。本研究は検尿異常の有無では長期腎予後に差はないことを示し、かつFGF-23の値も差がないことを示した。尿細管間質病変の進展にFGF-23が寄与することから同因子の存在が、SLE患者の腎予後と関係している可能性が示された。社会的意義としても今後の腎予後を推定する補助因子として　FGF-23が候補因子となれば腎生検などの侵襲性の高い検査をする患者を同定することができるため有益である。